Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1931935 | 1.00 | KMT2A (0.39) | KMT2AL3MBTL1MEN1SMN1; SMN2TRPV1 | |
| SCHEMBL1932582 | 1.00 | KMT2A (0.39) | KMT2AL3MBTL1MEN1SMN1; SMN2TRPV1 | |
| SCHEMBL6900081 | 0.93 | L3MBTL1 (0.41) | KMT2AL3MBTL1MEN1SMN1; SMN2TRPV1 | |
| SCHEMBL1933000 | 0.92 | L3MBTL1 (0.47) | KMT2AL3MBTL1MEN1SMN1; SMN2TRPV1 | |
| SCHEMBL1931965 | 0.91 | FFAR1 (0.41) | KMT2AL3MBTL1MEN1SMN1; SMN2TRPV1 | |
| SCHEMBL6901564 | 0.90 | L3MBTL1 (0.46) | KMT2AL3MBTL1SMN1; SMN2FFAR1ALDH1A1 | |
| SCHEMBL1933461 | 0.89 | NR1H4 (0.43) | KMT2AL3MBTL1MEN1SMN1; SMN2TRPV1 | |
| SCHEMBL1930559 | 0.89 | S1PR1 (0.44) | KMT2AL3MBTL1MEN1SMN1; SMN2TRPV1 | |
| SCHEMBL6901605 | 0.89 | MEN1 (0.40) | KMT2AL3MBTL1MEN1SMN1; SMN2TRPV1 | |
| SCHEMBL1932902 | 0.88 | L3MBTL1 (0.37) | KMT2AL3MBTL1MEN1SMN1; SMN2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018414-B2 | Substituted 3-phenylpropionic acids and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| US-9018414-B2 | Substituted 3-phenylpropionic acids and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| US-9018414-B2 | Substituted 3-phenylpropionic acids and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| US-20140142069-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| US-20140142069-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| US-20140142069-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| WO-2011051165-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142069-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | FABP3, PC, PAH | KMT2A 3688/4885L3MBTL1 2594/4885MEN1 4182/4885 |
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | FABP3, PC, PAH | KMT2A 3688/4885L3MBTL1 2594/4885MEN1 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.